proxyvotesnow.com

Home › Companies › Verona Pharma Plc › 2024-2025

Verona Pharma Plc 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Verona Pharma Plc’s Form 8-K, filed 2025-04-25 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 16Reported items
  • 199Asset managers
  • 1,258Fund votes
  • 2025-04-24Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Verona Pharma Plc in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Verona Pharma Plc

These tallies are Verona Pharma Plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-04-25 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Verona Pharma Plc — official shareholder meeting results, meeting held 2025-04-24
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Proposal 2. To re-elect Vikas Sinha as a Director of the Company. 584,744,10710,160,892-- 59,397,752-- Majority: yes
Proposal 3. To re-elect James Brady as a Director of the Company. 590,232,3554,675,044-- 59,395,352-- Majority: yes
Proposal 4. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024 and the report of the auditors thereon (the "2024 U.K. Annual Report"). 594,832,683163,844-- 59,306,224-- Majority: yes
Proposal 6. To re-appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders. 654,070,652163,844-- 59,306,224-- Majority: yes
Proposal 7. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025. 594,925,20346,368-- 59,331,180-- Majority: yes
Proposal 8. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. 429,961,621164,822,463-- 59,518,667-- Majority: yes

Source: Verona Pharma Plc, Form 8-K, filed with the SEC on 2025-04-25 — read the filing on EDGAR.

How asset managers voted at the Verona Pharma Plc 2024-2025 meeting

Each item below shows how the 199 asset managers that disclosed a Verona Pharma Plc vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Verona Pharma Plc’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory (non- binding) basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST 28%
FOR: 429,961,621AGAINST: 164,822,463

Verona Pharma Plc’s own tally for this item (“Proposal 8. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”): 429,961,621 for, 164,822,463 against, per its Form 8-K filed 2025-04-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 687,930,486 outstanding shares: 63% for, 24% against (86% of the company cast a for/against vote).

The 196 asset managers below cast 60% of the shares they voted on this item FOR (35,663,646 for, 24,143,486 against).

FOR 60%AGAINST 40%
FOR: 35,663,646 (59.6%)AGAINST: 24,143,486 (40.4%)NOT VOTED: 12,430 (0.0%)
Largest asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of the Company's named executive officers.” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
PERCEPTIVE ADVISORS LLC4,897,1130 00For
Janus Henderson3,735,08936,848 00For
Frazier Life Sciences Management, L.P.3,457,8500 00For
T. Rowe Price03,291,862 00Against
MUTUAL FUND SERIES TRUST2,877,8015,564 00For
RTW INVESTMENTS, LP2,755,8020 00For
NEA Management Company, LLC2,688,5660 00For
Federated Hermes2,535,5220 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.01,890,827 00Against
Putnam01,887,724 00Against
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC01,742,614 00Against
MAVERICK CAPITAL LTD1,648,2900 00For
Wellington01,575,013 00Against
Vivo Capital, LLC1,438,8060 00For
Point7201,420,324 00Against
Loomis Sayles01,397,039 00Against
JANUS INVESTMENT FUND1,163,8800 00For
JENNISON ASSOCIATES LLC01,105,918 00Against
Duquesne Family Office LLC1,002,0800 00For
Allspring0909,522 00Against
LORD, ABBETT & CO. LLC892,0280 00For
Lord Abbett825,6450 00For
PICTET ASSET MANAGEMENT SA760,9070 00For
SEB Investment Management AB0754,564 00Against
Fidelity0689,274 00Against

Showing the 25 largest of 196 asset managers. See all 196 in the interactive database.

2. To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 654,070,652AGAINST: 163,844

Verona Pharma Plc’s own tally for this item (“Proposal 6. To re-appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.”): 654,070,652 for, 163,844 against, per its Form 8-K filed 2025-04-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 687,930,486 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (12,536,646 for, 0 against).

FOR 100%
FOR: 12,536,646 (100.0%)
Largest asset managers voting on “To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
Federated Hermes1,267,7610 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Loomis Sayles534,1530 00For
Fidelity484,2820 00For
Prudential/PGIM470,0480 00For
Allspring431,8860 00For
Hartford352,9330 00For
BlackRock289,2820 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Vanguard112,9010 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Brighthouse62,5130 00For
ALPS ETF Trust61,9120 00For
Manager Directed Portfolios60,3880 00For
AIG/SunAmerica60,3010 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
Artisan42,4530 00For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

3. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 594,925,203AGAINST: 46,368

Verona Pharma Plc’s own tally for this item (“Proposal 7. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025.”): 594,925,203 for, 46,368 against, per its Form 8-K filed 2025-04-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 687,930,486 outstanding shares: 86% for, 0.1% against (86% of the company cast a for/against vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (12,536,646 for, 0 against).

FOR 100%
FOR: 12,536,646 (100.0%)
Largest asset managers voting on “To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
Federated Hermes1,267,7610 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Loomis Sayles534,1530 00For
Fidelity484,2820 00For
Prudential/PGIM470,0480 00For
Allspring431,8860 00For
Hartford352,9330 00For
BlackRock289,2820 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Vanguard112,9010 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Brighthouse62,5130 00For
ALPS ETF Trust61,9120 00For
Manager Directed Portfolios60,3880 00For
AIG/SunAmerica60,3010 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
Artisan42,4530 00For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

4. To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Companies Act does not apply to any such allotment. (Special Resolution)

CAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (12,511,219 for, 7 against).

FOR: 12,511,219 (100.0%)AGAINST: 7 (0.0%)
Largest asset managers voting on “To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
Federated Hermes1,267,7610 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Loomis Sayles534,1530 00For
Fidelity484,2820 00For
Prudential/PGIM470,0480 00For
Allspring431,8860 00For
Hartford352,9330 00For
BlackRock289,2820 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Vanguard112,9010 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Brighthouse62,5130 00For
ALPS ETF Trust61,9120 00For
Manager Directed Portfolios60,3880 00For
AIG/SunAmerica60,3010 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
Artisan42,4530 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. To re-elect Vikas Sinha as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

98% Majority: yes · of votes cast

FOR 98%
FOR: 584,744,107AGAINST: 10,160,892

Verona Pharma Plc’s own tally for this item (“Proposal 2. To re-elect Vikas Sinha as a Director of the Company.”): 584,744,107 for, 10,160,892 against, per its Form 8-K filed 2025-04-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 687,930,486 outstanding shares: 85% for, 1% against (86% of the company cast a for/against vote).

The 50 asset managers below cast 98% of the shares they voted on this item FOR (12,267,481 for, 243,745 against).

FOR 98%
FOR: 12,267,481 (98.1%)AGAINST: 243,745 (1.9%)
Largest asset managers voting on “To re-elect Vikas Sinha as a director of the Company.” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
Federated Hermes1,267,7610 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Loomis Sayles534,1530 00For
Fidelity279,290204,992 00For
Prudential/PGIM470,0480 00For
Allspring431,8860 00For
Hartford352,9330 00For
BlackRock289,2820 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Vanguard112,9010 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Brighthouse62,5130 00For
ALPS ETF Trust61,9120 00For
Manager Directed Portfolios60,3880 00For
AIG/SunAmerica60,3010 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
Artisan42,4530 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. To re-elect James Brady as a director of the Company.

DIRECTOR ELECTIONSMajority of the votes cast: yes

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 590,232,355AGAINST: 4,675,044

Verona Pharma Plc’s own tally for this item (“Proposal 3. To re-elect James Brady as a Director of the Company.”): 590,232,355 for, 4,675,044 against, per its Form 8-K filed 2025-04-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 687,930,486 outstanding shares: 86% for, 0.7% against (86% of the company cast a for/against vote).

The 50 asset managers below cast 98% of the shares they voted on this item FOR (12,306,234 for, 204,992 against).

FOR 98%
FOR: 12,306,234 (98.4%)AGAINST: 204,992 (1.6%)
Largest asset managers voting on “To re-elect James Brady as a director of the Company.” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
Federated Hermes1,267,7610 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Loomis Sayles534,1530 00For
Fidelity279,290204,992 00For
Prudential/PGIM470,0480 00For
Allspring431,8860 00For
Hartford352,9330 00For
BlackRock289,2820 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Vanguard112,9010 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Brighthouse62,5130 00For
ALPS ETF Trust61,9120 00For
Manager Directed Portfolios60,3880 00For
AIG/SunAmerica60,3010 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
Artisan42,4530 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

7. To Receive And Approve, As A Non-Binding Advisory Resolution, The U.K. Statutory Directors Remuneration Report For The Year Ended 31 December 2024.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

51.2% fund support · no official result

FOR 51.2%AGAINST 48.8%

The 35 asset managers below cast 51.2% of the shares they voted on this item FOR (2,494,542 for, 2,373,694 against).

FOR: 2,494,542 (51.2%)AGAINST: 2,373,694 (48.8%)
Largest asset managers voting on “To Receive And Approve, As A Non-Binding Advisory Resolution, The U.K. Statutory Directors Remuneration Report” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes1,267,7610 00For
Hood River Capital Management LLC609,3110 00For
Loomis Sayles0534,153 00Against
Affinity Asset Advisors, LLC512,7800 00For
Prudential/PGIM0396,548 00Against
Hartford0352,933 00Against
BlackRock0302,203 00Against
GW&K Investment Management, LLC0194,149 00Against
Vanguard080,979 00Against
John Hancock078,922 00Against
Northwestern Mutual067,071 00Against
Manager Directed Portfolios60,3880 00For
Russell Investments047,785 00Against
Neuberger Berman045,711 00Against
Guardian Variable Products Trust043,879 00Against
MassMutual039,899 00Against
AMG FUNDS34,3000 00For
Fidelity033,723 00Against
Treasurer of the State of North Carolina033,178 00Against
CLEARWATER INVESTMENT TRUST033,064 00Against
Advisors' Inner Circle Fund III025,737 00Against
MML SERIES INVESTMENT FUND016,315 00Against
New York Life013,858 00Against
AMG Funds IV08,479 00Against
Argent Trust Co8,1500 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

8. To re-elect Kenneth Cunningham as a director of the Company.

DIRECTOR ELECTIONS

76% fund support · no official result

FOR 76%AGAINST 24%

The 28 asset managers below cast 76% of the shares they voted on this item FOR (2,670,554 for, 823,435 against).

FOR: 2,670,554 (76.4%)AGAINST: 823,435 (23.6%)
Largest asset managers voting on “To re-elect Kenneth Cunningham as a director of the Company.” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes1,267,7610 00For
Loomis Sayles0534,153 00Against
Prudential/PGIM396,5480 00For
Hartford352,9330 00For
BlackRock0289,282 00Against
Vanguard80,9790 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Manager Directed Portfolios60,3880 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
MassMutual39,8990 00For
AMG FUNDS34,3000 00For
Fidelity33,7230 00For
CLEARWATER INVESTMENT TRUST33,0640 00For
Advisors' Inner Circle Fund III25,7370 00For
MML SERIES INVESTMENT FUND16,3150 00For
New York Life13,8580 00For
AMG Funds IV8,4790 00For
Nationwide7,4790 00For
Brighthouse4,7950 00For
TRUST FOR PROFESSIONAL MANAGERS3,9690 00For
Forethought Variable Insurance Trust2,2780 00For
Advisors Preferred Trust1,7520 00For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

9. To Receive And Adopt The U.K. Statutory Annual Accounts And Directors Report For The Year Ended 31 December 2024.

CORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 28 asset managers below cast 100% of the shares they voted on this item FOR (3,493,989 for, 0 against).

FOR: 3,493,989 (100.0%)
Largest asset managers voting on “To Receive And Adopt The U.K. Statutory Annual Accounts And Directors Report For The Year Ended 31 December 20” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes1,267,7610 00For
Loomis Sayles534,1530 00For
Prudential/PGIM396,5480 00For
Hartford352,9330 00For
BlackRock289,2820 00For
Vanguard80,9790 00For
John Hancock78,9220 00For
Northwestern Mutual67,0710 00For
Manager Directed Portfolios60,3880 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
Guardian Variable Products Trust43,8790 00For
MassMutual39,8990 00For
AMG FUNDS34,3000 00For
Fidelity33,7230 00For
CLEARWATER INVESTMENT TRUST33,0640 00For
Advisors' Inner Circle Fund III25,7370 00For
MML SERIES INVESTMENT FUND16,3150 00For
New York Life13,8580 00For
AMG Funds IV8,4790 00For
Nationwide7,4790 00For
Brighthouse4,7950 00For
TRUST FOR PROFESSIONAL MANAGERS3,9690 00For
Forethought Variable Insurance Trust2,2780 00For
Advisors Preferred Trust1,7520 00For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

10. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report FOR the year ended December 31, 2024.

COMPENSATION

56% fund support · no official result

FOR 56%AGAINST 44%

The 27 asset managers below cast 56% of the shares they voted on this item FOR (5,025,488 for, 3,992,036 against).

FOR: 5,025,488 (55.7%)AGAINST: 3,992,036 (44.3%)
Largest asset managers voting on “To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Repor” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,877,8015,564 00For
T. Rowe Price01,479,841 00Against
JANUS INVESTMENT FUND1,163,8800 00For
Putnam0910,935 00Against
Lord Abbett825,6450 00For
Fidelity0450,559 00Against
Allspring0431,886 00Against
American Century0244,311 00Against
Legg Mason0184,500 00Against
Prudential/PGIM73,5000 00For
ALPS ETF Trust061,912 00Against
AIG/SunAmerica060,301 00Against
Brighthouse057,718 00Against
Artisan042,453 00Against
Columbia Threadneedle38,7530 00For
Vanguard31,9220 00For
AdvisorShares Trust023,160 00Against
Equitable019,284 00Against
STEWARD FUNDS, INC.015,952 00Against
PENN SERIES FUNDS INC7,4890 00For
Goldman Sachs5,7560 00For
ProShares03,200 00Against
Strategy Shares4550 00For
First Trust0350 00Against
Vident Advisory, LLC2870 00For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

11. To re-elect Kenneth Cunningham, M.D. as a director of the Company.

DIRECTOR ELECTIONS

97% fund support · no official result

FOR 97%

The 26 asset managers below cast 97% of the shares they voted on this item FOR (8,754,527 for, 262,710 against).

FOR: 8,754,527 (97.1%)AGAINST: 262,710 (2.9%)
Largest asset managers voting on “To re-elect Kenneth Cunningham, M.D. as a director of the Company.” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Fidelity245,567204,992 00For
Allspring431,8860 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Prudential/PGIM73,5000 00For
ALPS ETF Trust61,9120 00For
AIG/SunAmerica60,3010 00For
Brighthouse057,718 00Against
Artisan42,4530 00For
Columbia Threadneedle38,7530 00For
Vanguard31,9220 00For
AdvisorShares Trust23,1600 00For
Equitable19,2840 00For
STEWARD FUNDS, INC.15,9520 00For
PENN SERIES FUNDS INC7,4890 00For
Goldman Sachs5,7560 00For
ProShares3,2000 00For
Strategy Shares4550 00For
First Trust3500 00For
Investment Managers Series Trust II1030 00For

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

12. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024.

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 26 asset managers below cast 100% of the shares they voted on this item FOR (9,017,237 for, 0 against).

FOR: 9,017,237 (100.0%)
Largest asset managers voting on “To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, ” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
T. Rowe Price1,479,8410 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Fidelity450,5590 00For
Allspring431,8860 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Prudential/PGIM73,5000 00For
ALPS ETF Trust61,9120 00For
AIG/SunAmerica60,3010 00For
Brighthouse57,7180 00For
Artisan42,4530 00For
Columbia Threadneedle38,7530 00For
Vanguard31,9220 00For
AdvisorShares Trust23,1600 00For
Equitable19,2840 00For
STEWARD FUNDS, INC.15,9520 00For
PENN SERIES FUNDS INC7,4890 00For
Goldman Sachs5,7560 00For
ProShares3,2000 00For
Strategy Shares4550 00For
First Trust3500 00For
Investment Managers Series Trust II1030 00For

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

13. To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11,

CAPITAL STRUCTURE

100% fund support · no official result

FOR 100%

The 21 asset managers below cast 100% of the shares they voted on this item FOR (6,052,436 for, 0 against).

FOR: 6,052,436 (100.0%)
Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price1,479,8410 00For
JANUS INVESTMENT FUND1,163,8800 00For
Putnam910,9350 00For
Lord Abbett825,6450 00For
Fidelity450,5590 00For
Allspring431,8860 00For
American Century244,3110 00For
Legg Mason184,5000 00For
Prudential/PGIM73,5000 00For
ALPS ETF Trust61,9120 00For
AIG/SunAmerica60,3010 00For
Artisan42,4530 00For
Columbia Threadneedle38,7530 00For
Vanguard31,9220 00For
Equitable19,2840 00For
STEWARD FUNDS, INC.15,9520 00For
PENN SERIES FUNDS INC7,4890 00For
Goldman Sachs5,7560 00For
ProShares3,2000 00For
First Trust3500 00For
Aberdeen70 00For

14. To Authorize The Board Of Directors To Exercise All The Powers Of The Company To Allot Shares In The Company Or Grant Rights To Subscribe For Or To Convert Any Security Into Shares In The Company Up To An Aggregate Nominal Amount Of PS7,031,895 (Being Up To A Maximum Of 140,637,892 Shares Representing 20% Of The Company's Existing Ordinary Share Capital As At The Close Of Business On March 11, 202

CAPITAL STRUCTURE

100% fund support · no official result

FOR 100%

The 18 asset managers below cast 100% of the shares they voted on this item FOR (2,437,682 for, 0 against).

FOR: 2,437,682 (100.0%)
Largest asset managers voting on “To Authorize The Board Of Directors To Exercise All The Powers Of The Company To Allot Shares In The Company O” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes1,267,7610 00For
Prudential/PGIM396,5480 00For
Hartford352,9330 00For
Vanguard80,9790 00For
Northwestern Mutual67,0710 00For
Russell Investments47,7850 00For
Neuberger Berman45,7110 00For
MassMutual39,8990 00For
Fidelity33,7230 00For
CLEARWATER INVESTMENT TRUST33,0640 00For
Advisors' Inner Circle Fund III25,7370 00For
MML SERIES INVESTMENT FUND16,3150 00For
New York Life13,8580 00For
Nationwide7,4790 00For
Brighthouse4,7950 00For
Forethought Variable Insurance Trust2,2780 00For
Victory Capital1,3210 00For
Principal4250 00For

15. To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11, 2025

CAPITAL STRUCTURE

100% fund support · no official result

FOR 100%

The 15 asset managers below cast 100% of the shares they voted on this item FOR (4,021,108 for, 0 against).

FOR: 4,021,108 (100.0%)
Largest asset managers voting on “To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company o” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,883,3650 00For
Loomis Sayles534,1530 00For
BlackRock289,2820 00For
John Hancock78,9220 00For
Manager Directed Portfolios60,3880 00For
Brighthouse57,7180 00For
Guardian Variable Products Trust43,8790 00For
AMG FUNDS34,3000 00For
AdvisorShares Trust23,1600 00For
AMG Funds IV8,4790 00For
TRUST FOR PROFESSIONAL MANAGERS3,9690 00For
Advisors Preferred Trust1,7520 00For
Exchange Place Advisors Trust1,1830 00For
Strategy Shares4550 00For
Investment Managers Series Trust II1030 00For

16. Approve Remuneration Report

COMPENSATION

0% fund support · no official result

AGAINST 100%

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 112,832 against).

AGAINST: 112,832 (100.0%)
Largest asset managers voting on “Approve Remuneration Report” at Verona Pharma Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Desjardins Global Asset Management Inc.083,589 00Against
GuideStone025,420 00Against
Liberty Mutual Group Asset Management Inc.03,823 00Against

Largest Verona Pharma Plc shareholders voting in 2024-2025

Ranked by the number of Verona Pharma Plc shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 687,930,486 shares outstanding at the time of that meeting.

Top Verona Pharma Plc shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1PERCEPTIVE ADVISORS LLC 0.71%
2Janus Henderson 0.55%
3Frazier Life Sciences Management, L.P. 0.50%
4T. Rowe Price 0.48%
5MUTUAL FUND SERIES TRUST 0.42%
6RTW INVESTMENTS, LP 0.40%
7NEA Management Company, LLC 0.39%
8Federated Hermes 0.37%
9ADAGE CAPITAL PARTNERS GP, L.L.C. 0.27%
10Putnam 0.27%

Reported Verona Pharma Plc ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Verona Pharma Plc beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
RA Capital Management affiliates 9.05% DEF14A
Perceptive Advisors LLC 7.64% DEF14A
Growth Equity Opportunities 17, LLC 4.75% 13D
Maverick Capital, Ltd. 3.64% 13G
David Zaccardelli, Pharm.D. 1.67% DEF14A
Mark W. Hahn 1.54% DEF14A
Kathleen Rickard, M.D. 0.38% DEF14A
T. Rowe Price 0.27% 13F
Claire Poll 0.25% DEF14A
Morgan Stanley 0.24% 13F

Percentages above are of 687,930,486 shares outstanding, as reported by Verona Pharma Plc on its Form 10-Q dated 2025-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Verona Pharma Plc’s 10-Q dated 2025-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Verona Pharma Plc's shareholder meeting held 2025-04-24, in the 2024-2025 proxy season, 199 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,258 separate fund positions. Their filings are grouped here into 16 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of the Company's named… — FOR was 72% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Verona Pharma Plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-04-25.

Verona Pharma Plc proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.